Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of Telacebec (Q203) in Healthy Volunteers
NCT02530710Phase 1Completed
- Sponsor
- Qurient Co., Ltd.
- Start
- Aug 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Tuberculosis (TB) comparing Q203 with Placebo (2 arms). Primary endpoint: Adverse Events. Started Aug 2015; status: completed.
02
Drugs
Telacebec
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02530710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530710.